Sir-I wish to respond to the letter by Sánchez et al. [1] that described acalculous cholecystitis (AC) in association with Plasmodium falciparum malaria. There are important differences between their case and the one that Dr. Al-Azragi and I reported [2] . In the case reported by Sánchez et al. [1] , the results of multiple smears for malaria parasites were negative at the time of presentation of AC. Treatment with broad-spectrum antibiotics resulted in a clinical and radiological response, and at the time of the patient's readmission to the hospital, a bacterial pathogen was isolated from the bloodstream. Demonstration of the malaria infection occurred only after the AC had resolved. This clearly contrasts with the case that Dr. Al-Azragi and I reported [2] , in which the patient failed to respond to broad-spectrum antibiotics and in which no bacterial pathogen was isolated from the blood cultures. Clinical and radiological resolution occurred only after administration of specific therapy for P. falciparum.
I believe that the facts associated with the case presented by Sánchez et al. suggest that the cause of the AC was a Shigella infection that relapsed after treatment. The fever that persisted, despite antibiotic therapy, at the time of the patient's readmission to the hospital was most likely caused by malaria.
Reassuring Safety Profile of Moxifloxacin
Sir-During the year 2000, Hooper [1] and Ball [2] reviewed the adverse drug reaction (ADR) profiles of the quinolone class antimicrobial agents. Within the last year, 2 quinolones have been recognized to produce either unacceptable hepatotoxicity (trovafloxacin) or cardiotoxicity (grepafloxacin) and have had their use restricted or have been withdrawn. Since then the US Food and Drug Administration (FDA) has approved 2 further quinolones (moxifloxacin and gatifloxacin) for use, and required that another (levofloxacin) carry additional safety labeling. The new drug application for a fourth quinolone (clinafloxacin) has been withdrawn from the approval process.
These events have raised serious questions about the continued utility of the quinolone antimicrobials and about perceptions of toxicity. In an effort to confront these issues, this letter presents data on moxifloxacin both from the database of ongoing clinical trials [3] and from clinical experience, which currently includes 2,235,000 patients.
A number of adverse drug reactions are recognized as being fluoroquinoloneclass effects. Both their incidence and severity vary widely between class members, but they are rarely severe. They include CNS effects (commonly, dizziness and headache), gastrointestinal effects (such as diarrhea, nausea, abdominal discomfort, and vomiting), and skin reactions (mainly pruritis, and rashes; phototoxicity is rarely associated with newer members of the class).
The new methoxy members of this class (moxifloxacin and gatifloxacin) have been thoroughly evaluated in clinical trials for these anticipated class reactions; incidences have been similar to those associated with the older members of the class, and overall discontinuation rates have been ∼3% [4, 5] . Both agents have a low phototoxicity potential and appear to have no significant associated neurotoxicity and hepatotoxicity. For moxifloxacin, to date there have been no reports of the adverse events that have been associated with treatment with other compounds, such as hepatotoxicity associated with trovafloxacin therapy and immunological reactions associated with treatment with temafloxacin or tosufloxacin.
It has been reported elsewhere [2] that other agents (sparfloxacin, grepafloxacin, erythromycin, and clarithromycin) have prolonged QT in either animals or hu- mans, and we observed this phenomenon during rapid, high-dose iv infusion in phase I studies. Therefore, moxifloxacin was studied in detail to determine if it prolonged the QTc (i.e., the heart rate-corrected QT interval) after both iv and oral administration (data on file, Bayer AG). This observation led to an unprecedented program to collect electrocardiogram (ECG) data for patients receiving an antimicrobial compound. Detailed ECG profiles for 2650 patients were analyzed. The depth and quality of this study was subsequently endorsed by the FDA Advisory Committee [6] .
Data from this population that were analyzed with use of the CPMP (Committee for Pharmaceutical and Medicinal Products) criteria revealed significant QTc changes in 2.8% of patients treated with moxifloxacin, 3.7% of patients treated with clarithromycin, and 2.2% of all other patients [3] . A mean QTc prolongation of 6 ms was reported for patients treated with moxifloxacin (SD, ‫82ע‬ ms, which indicates that variation accounts for some of the effect). No clinical events, such as syncope or arrhythmias, were observed in patients who had significant QT prolongation. The normal intra-individual variability of the QTc is 25-30 ms, and it can be as high as 70 ms. Furthermore, an analysis of 6178 patients treated with moxifloxacin in 26 clinical trials revealed no episodes of torsade de pointes (a multifocal ventricular tachyarrhythmia associated with QT prolongation) and no deaths due to cardiac adverse drug events [6] .
In 1999, reports of ADRs linked to quinolone treatment and associated regulatory action drew attention to the quinolone class, and therefore it was considered essential that patients treated with moxifloxacin undergo detailed followup. Recently, 2 large postmarketing observational studies (PMOS) programs have been completed, which included almost 35,000 patients who were treated in daily clinical practice (data on file, Bayer AG). These studies examined all known quinolone class effects (and any previously unseen reactions) and have reported no unusual adverse events.
Additionally, all unsolicited reports of adverse events in patients treated with moxifloxacin that have been forwarded to the regulatory authorities or the manufacturer are being vigorously followed up. Tables 1 and 2 present the comparative incidence of the most common adverse reactions among patients enrolled in clinical trials and among those enrolled in PMOS. Predictably, the highest incidence of events was reported in the clinical trial group. As of 30 September 2000, moxifloxacin had been prescribed for 2,235,000 patients. Of special interest are the 200 patients described as having cardiovascular ADRs; for 132 of these (0.006% of the total 2,235,000), the ADR was defined as "serious" by the authors (not all the events were drug-related). However, 1 of these ADRs was a case of successfully cardioconverted torsade de pointes that occurred in an 83-year-old woman who was being treated in an intensive care unit for severe cerebrovascular/coronary heart disease. This patient had significant hypokalemia (potassium level, 2.98 mg/mL) and a baseline QTc of 490 ms; she had received digoxin therapy and other factors that predisposed her to cardiac events. Examination of the other reports (data on file, Bayer AG) revealed no other cases of torsades de pointes, malignant ventricular tachyarrthymias, or deaths due to cardiac events.
Further detailed analysis of data on the 2,235,000 patients treated with moxifloxacin revealed no cases of photosensitivity or other significant skin reaction, no cases of arthritis and/or tendinitis, and only 3 cases of a transient hepatic event (however, none of these were of the hypersensitivity type that is associated with trovafloxacin treatment). Overall, 905 of the 2,235,000 patients (0.04%) were reported to have experienced a spontaneous adverse event (not all of these were specifically drug-related reactions). There was no evidence of QTc prolongation, serious arrhythmias, severe hepatic toxicity, or CNS reactions. This safety profile is similar to that observed internationally for ciprofloxacin during its first year of clinical use, and it is similar to that observed for other widely used quinolones.
